Clinical evaluation of adriamycin, a new antitumour antibiotic
- PMID: 5257148
- PMCID: PMC1984262
- DOI: 10.1136/bmj.3.5669.503
Clinical evaluation of adriamycin, a new antitumour antibiotic
Abstract
Adriamycin, a new antitumour antibiotic of the anthracycline group with a structural formula very similar to daunorubicin, has proved to have potent tumour-growth-inhibiting properties, and to be particularly effective in childhood malignancies. Though adriamycin produces a higher percentage of side-effects than daunorubicin-namely, stomatitis and alopecia-a lower dosage may be used for therapy.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources